Mandate

Beijer Byggmaterial to acquire Bygg-Ole

October 10, 2018 M&A

Vinge has advised Beijer Byggmaterial AB (“Beijer Byggmaterial”) in connection with Beijer Byggmaterial entering into an agreement to acquire Nacka Trä & Byggvaror, Sven Gustafsson AB ("Bygg Ole"). Completion of the transaction is subject to customary conditions.

Bygg Ole is a family owned company with stores in Nacka, Värmdö, Märsta och Saltsjö Boo. Bygg Ole has an annual turnover of more than MSEK 700 and employs more than 200 employees. Beijer Byggmaterial is Sweden’s largest wholly owned retailer and distributor of building materials with 69 stores across Sweden. With the acquisition of Bygg Ole, Beijer Byggmaterial grows to have a total of 73 stores in Sweden. Beijer Byggmaterial is part of Stark Group, the largest retailer and distributor of building materials in the Nordic region with operations in Denmark, Greenland, Norway, Sweden and Finland. 

Vinge’s team consisted of, among others, Jonas Bergström, Linda Sengul and Anna Thoms (M&A), Hayaat Ibrahim (Corporate Commercial), Kristoffer Larsson (Real Property/Lease Agreements) and Xandra Ståhlberg (Anti Trust).
 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024